Literature DB >> 22948766

Polycystic Ovary-Like Abnormalities (PCO-L) in women with functional hypothalamic amenorrhea.

G Robin1, C Gallo, S Catteau-Jonard, C Lefebvre-Maunoury, P Pigny, A Duhamel, D Dewailly.   

Abstract

CONTEXT: In the general population, about 30% of asymptomatic women have polycystic ovary-like abnormalities (PCO-L), i.e. polycystic ovarian morphology (PCOM) at ultrasound and/or increased anti-Müllerian hormone (AMH) serum level. PCOM has also been reported in 30-50% of women with functional hypothalamic amenorrhea (FHA).
OBJECTIVE: The aim of this study was to verify whether both PCOM and excessive AMH level indicate PCO-L in FHA and to elucidate its significance.
DESIGN: We conducted a retrospective analysis using a database and comparison with a control population.
SETTING: Subjects received ambulatory care in an academic hospital. PATIENTS: Fifty-eight patients with FHA were compared to 217 control women with nonendocrine infertility and body mass index of less than 25 kg/m(2).
INTERVENTIONS: There were no interventions. MAIN OUTCOME MEASURES: We measured serum testosterone, androstenedione, FSH, LH, AMH, and ovarian area values. The antral follicle count (AFC) was used as a binary variable (i.e. negative or positive) because of the evolution of its sensitivity over the time of this study. The ability of these variables (except AFC) to detect PCO-L in both populations was tested by cluster analysis.
RESULTS: One cluster (cluster 2) suggesting PCO-L was detected in the control population (n = 52; 24%), whereas two such clusters were observed in the FHA population (n = 22 and n = 6; 38 and 10%; clusters 2 and 3, respectively). Cluster 2 in FHA had similar features of PCO-L as cluster 2 in controls, with higher prevalence of positive AFC (70%) and PCOM (70%), higher values of ovarian area and higher serum AMH (P < 0.0001 for all), and testosterone levels (P < 0.01) than in cluster 1. Cluster 3 in FHA was peculiar, with frankly elevated AMH levels. In the whole population (controls + FHA), PCO-L was significantly associated with lower FSH values (P < 0.0001).
CONCLUSION: PCO-L in FHA is a frequent and usually incidental finding of unclear significance, as in controls. The association of PCO-L with hypothalamic amenorrhea should not lead to a mistaken diagnosis of PCOS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22948766     DOI: 10.1210/jc.2012-1836

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  10 in total

1.  Circulating profile of Activin-Follistatin-Inhibin Axis in women with hypothalamic amenorrhea in response to leptin treatment.

Authors:  Eirini Bouzoni; Nikolaos Perakakis; Christos S Mantzoros
Journal:  Metabolism       Date:  2020-10-10       Impact factor: 8.694

2.  Polycystic Ovary Syndrome Phenotype D Versus Functional Hypothalamic Amenorrhea With Polycystic Ovarian Morphology: A Retrospective Study About a Frequent Differential Diagnosis.

Authors:  Klara Beitl; Didier Dewailly; Rudolf Seemann; Marlene Hager; Jakob Bünker; Daniel Mayrhofer; Iris Holzer; Johannes Ott
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-02       Impact factor: 6.055

Review 3.  The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited.

Authors:  Robert L Rosenfield; David A Ehrmann
Journal:  Endocr Rev       Date:  2016-07-26       Impact factor: 19.871

4.  Is Ovarian Reserve Impacted in Anorexia Nervosa?

Authors:  Sarah Pitts; Suzanne E Dahlberg; Jenny Sadler Gallagher; Catherine M Gordon; Amy D DiVasta
Journal:  J Pediatr Adolesc Gynecol       Date:  2020-12-03       Impact factor: 1.814

Review 5.  Role of Anti-Müllerian Hormone in pathophysiology, diagnosis and treatment of Polycystic Ovary Syndrome: a review.

Authors:  Agathe Dumont; Geoffroy Robin; Sophie Catteau-Jonard; Didier Dewailly
Journal:  Reprod Biol Endocrinol       Date:  2015-12-21       Impact factor: 5.211

6.  Differentiation between polycystic ovary syndrome and polycystic ovarian morphology by means of an anti-Müllerian hormone cutoff value.

Authors:  Do Kyeong Song; Jee-Young Oh; Hyejin Lee; Yeon-Ah Sung
Journal:  Korean J Intern Med       Date:  2016-11-30       Impact factor: 2.884

7.  Polycystic ovary syndrome phenotype does not have impact on oocyte morphology.

Authors:  Audrey Uk; Christine Decanter; Camille Grysole; Laura Keller; Hélène Béhal; Mauro Silva; Didier Dewailly; Geoffroy Robin; Anne-Laure Barbotin
Journal:  Reprod Biol Endocrinol       Date:  2022-01-05       Impact factor: 5.211

8.  Basal and dynamic relationships between serum anti-Müllerian hormone and gonadotropins in patients with functional hypothalamic amenorrhea, with or without polycystic ovarian morphology.

Authors:  Marlene Hager; Johannes Ott; Julian Marschalek; Marie-Louise Marschalek; Clemens Kinsky; Rodrig Marculescu; Didier Dewailly
Journal:  Reprod Biol Endocrinol       Date:  2022-07-04       Impact factor: 4.982

9.  Does polycystic ovarian morphology influence the response to treatment with pulsatile GnRH in functional hypothalamic amenorrhea?

Authors:  Agathe Dumont; Didier Dewailly; Pauline Plouvier; Sophie Catteau-Jonard; Geoffroy Robin
Journal:  Reprod Biol Endocrinol       Date:  2016-04-29       Impact factor: 5.211

Review 10.  Current understanding of hypothalamic amenorrhoea.

Authors:  Rachel E Roberts; Linda Farahani; Lisa Webber; Channa Jayasena
Journal:  Ther Adv Endocrinol Metab       Date:  2020-07-30       Impact factor: 3.565

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.